- Company recently announced that its 2015 and 2016 YE audits have been finalized, its Form 10 has been submitted and it has commenced its 2017 fiscal year audit
- Strategically working to improve treatments for different diseases on a global scale
- Addressing the national health crisis of opioid addiction
Earth Science Tech, Inc. (OTC: ETST), an innovative biotech company focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing high-grade hemp cannabidiol (CBD), recently announced that its 2015 and 2016 audit process has been finalized and Form 10 has been submitted. ETST has now begun the 2017 fiscal year audit, which is required to uplist to the OTCQB Venture Market, along with the approved Form 10.
In a news release (http://cnw.fm/Gu72a), Dr. Michel Aube, CEO and chief science officer of ETST, stated, “Transparency is a key tool that we needed to accelerate the growth of our business. Since all of our amazing projects are ongoing with our partners, investor confidence will grow, and we will be able to complete our first big round of financing. We are in touch with institutional and private investors that were waiting for ETST to become a fully reporting company before investing the necessary amount to commercialize our projects. We can now resume our discussions with them.” Becoming a fully reporting OTCQB company is expected to open many opportunities while simultaneously boosting investor confidence. An Audio Press Release (APR) of this announcement is available at http://cnw.fm/SNc0C .
Earth Science Tech is a biotechnology company based in Florida that’s focused on the science, research and study of high-grade hemp cannabinoid (CBD) oil as a nutraceutical and dietary supplement. ETST is working to improve treatments for different diseases on a global scale through its subsidiaries: Earth Science Pharmaceutical, Cannabis Therpeutics Inc., Kannabidioid Inc., and Canna Inno Laboratories Inc. Its Earth Science Pharmaceutical subsidiary is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases (STIs). Cannabis Therapeutics is also a subsidiary of ETST, and it was formed as an emerging biotech company poised to become a world leader in CBD research and development. In the recreational space, ETST owns Kannabidioid, a subsidiary focused on manufacturing and distributing vapes/e-liquids and gummy edibles. The acquisition of Canna Inno Laboratories in Quebec granted ETST access to the growing Canadian market and government funding. It has already received a supporting grant for innovation in the pharmaceutical industry. The company has plans to apply for additional funding under Canada’s Scientific Research and Experimental Development Tax Credit program.
ETST has also taken on a new fight – opioid addiction. Human clinical trials are scheduled to begin in 2019. With the opioid epidemic projected to claim nearly 500,000 American lives by 2027 (http://cnw.fm/m7I0V), the company seeks to improve the treatment of those fighting dependency. The goal of the study is to reduce the cravings of opioid addicts and reduce the danger of side effects while making the drug more effective. This is just one of many ways that ETST is committed to improving treatments for different diseases worldwide.
Additional transparency, a strengthening of current subsidiaries through new studies and markets, the rise of the cannabis industry, access to government grants in Canada and a commitment to finding solutions to the national epidemic of opioid addiction are all small key parts in a much larger strategic plan for accelerated growth.
For more information, visit the company’s website at www.EarthScienceTech.com
More from CannabisNewsWire
About HempWire
HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
